2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1014

The Rheumatic Disease Data Refinery: A Case Study in Integrative Genomics Reveals Complex IFN Signatures in Therapeutic Studies in SLE
Abstract Number: 288

The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages
Abstract Number: 273

The Risk Factors of Developing Adult T Cell Leukemia (ATL) in Human T Cell Leukemia Virus Type 1 (HTLV-1) Positive Patients with Rheumatoid Arthritis in Endemic Area, Japan; A Retrospective Cohort Study
Abstract Number: 2386

The Risk Factors of Newly Developing/Worsening Pulmonary Abnormalities in Rheumatoid Arthritis
Abstract Number: 883

The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Ankylosing Spondylitis: A General Population-Based Study
Abstract Number: 1964

The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
Abstract Number: 2759

The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Abstract Number: 2788

The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial
Abstract Number: 1718

The Role and Function of Monocyte-Derived Fibroblast-like Cells in Multi-Organ Fibrosis in Systemic Sclerosis
Abstract Number: 393

The Role of Follicular Helper 17 T Cells in Glucose-6-Phosphate Isomerase Induced Arthritis
Abstract Number: 2186

The Role of Hip Injury in Pain Exacerbation in Hip Osteoarthritis: an Internet-Based Case-Crossover Study
Abstract Number: 2595

The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
Abstract Number: 2497

The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study
Abstract Number: 2575

The Role of Interferon in Autoimmune-Susceptible Ro60 Knockout Mice
Abstract Number: 2233

The Role of Life Purpose in Disability and Depression in Patients with Acute Low Back Pain

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].